Advertisement

Quantification and Qualification of Stem Cells From Blood After Mobilization With Filgrastim, and Concentration Using a Platelet-Rich Plasma System

      Purpose

      To determine the cellular composition of a product created with peripheral blood harvested after systemic mobilization with filgrastim and processed with one point-of-care blood concentrating system, i.e., a platelet-rich plasma (PRP) system. The second purpose was to compare mobilized platelet-rich plasma (M-PRP) with a concentrated bone marrow aspirate (cBMA) and a PRP created from the same subjects with the same PRP system.

      Methods

      Ten healthy volunteer subjects were recruited for collection and analysis of 3 tissue sources: non-treated peripheral blood, bone marrow aspirate, and filgrastim-mobilized peripheral blood, involving 4 doses of weight-based filgrastim. One point-of-care blood and bone marrow concentrating system was used to create 3 products: PRP, cBMA, and M-PRP. Automated hematologic analysis was performed on all products to quantify total red blood cells, white blood cells (WBCs), monocyte, platelet, and hematopoietic progenitor cell (HPC) concentrations. Flow cytometry was used to determine hematopoietic and mesenchymal progenitor cell populations. Lastly, concentrates were cultured and fibroblast colony-forming units (CFU-F) and morphology of adherent cells were evaluated.

      Results

      M-PRP contained a greater concentration of WBC (mean difference = 53.2 k/μL; P < .0001), monocytes (mean difference = 8.3 k/μL; P = .002), and a trend toward a greater concentration of HPC (mean difference = 200.5 /μL; P = .060) when compared with PRP. M-PRP contained a greater concentration of monocytes (mean difference = 5.5 k/μL; P = .017) and a trend toward a greater concentration of platelets (mean difference = 348 k/μL; P = .051) and HPC (mean difference = 193.4 /μL; P = .068) when compared with cBMA. M-PRP had a similar concentration of platelets to PRP (mean difference = 110 k/μL; P = .051) and PRP had a greater concentration than cBMA (mean difference = 458 k/μL; P = .003). cBMA remained the only product capable of producing CFU-Fs (446 ± 247 /mL) as neither the M-PRP nor PRP produced CFU-Fs. M-PRP produced colonies consistent with WBC.

      Conclusions

      M-PRP, produced with filgrastim mobilized blood and a proprietary PRP system, contained more total WBCs, monocytes, platelets, and HPCs than cBMA and more WBCs, monocytes, and HPCs than PRP.

      Clinical Relevance

      Filgrastim mobilized PRP may be an alternative to cBMA for use as a point-of-care product for orthopaedic treatments.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Arthroscopy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Marycz K.
        • Mierzejewska K.
        • Smieszek A.
        • et al.
        Endurance exercise mobilizes developmentally early stem cells into peripheral blood and increases their number in bone marrow: Implications for tissue regeneration.
        Stem Cells Int. 2016; 2016: 5756901
        • Rochefort G.Y.
        • Delorme B.
        • Lopez A.
        • et al.
        Multipotential mesenchymal stem cells are mobilized into peripheral blood by hypoxia.
        Stem Cells. 2006; 24: 2202-2208
        • Hauser R.A.
        • Orlofsky A.
        Regenerative injection therapy with whole bone marrow aspirate for degenerative joint disease: A case series.
        Clin Med Insights Arthritis Musculoskelet Disord. 2013; 6: 65-72
        • Hernigou P.
        • Flouzat Lachaniette C.H.
        • Delambre J.
        • et al.
        Biologic augmentation of rotator cuff repair with mesenchymal stem cells during arthroscopy improves healing and prevents further tears: A case-controlled study.
        Int Orthop. 2014; 38: 1811-1818
        • Hernigou P.
        • Poignard A.
        • Beaujean F.
        • Rouard H.
        Percutaneous autologous bone-marrow grafting for nonunions.
        J. Bone Joint Surg. 2005; 87: 1430-1437
        • Hernigou P.
        • Poignard A.
        • Zilber S.
        • Rouard H.
        Cell therapy of hip osteonecrosis with autologous bone marrow grafting.
        Indian J Orthop. 2008; 43: 40-45
        • Saw K.Y.
        • Anz A.
        • Siew-Yoke Jee C.
        • et al.
        Articular cartilage regeneration with autologous peripheral blood stem cells versus hyaluronic acid: a randomized controlled trial.
        Arthroscopy. 2013; 29: 684-694
        • Sivasubramaniyan K.
        • Ilas D.C.
        • Harichandan A.
        • et al.
        Bone marrow-harvesting technique influences functional heterogeneity of mesenchymal stem/stromal cells and cartilage regeneration.
        Am J Sports Med. 2018; 46: 3521-3531
        • Fennema E.M.
        • Renard A.J.
        • Leusink A.
        • van Blitterswijk C.A.
        • de Boer J.
        The effect of bone marrow aspiration strategy on the yield and quality of human mesenchymal stem cells.
        Acta Orthop. 2009; 80: 618-621
        • Hernigou P.
        • Homma Y.
        • Flouzat Lachaniette C.H.
        • et al.
        Benefits of small volume and small syringe for bone marrow aspirations of mesenchymal stem cells.
        Int Orthop. 2013; 37: 2279-2287
        • Gronkjaer M.
        • Hasselgren C.F.
        • Ostergaard A.S.
        • et al.
        Bone marrow aspiration: A randomized controlled trial assessing the quality of bone marrow specimens using slow and rapid aspiration techniques and evaluating pain intensity.
        Acta Haematol. 2016; 135: 81-87
        • Hyer C.F.
        • Berlet G.C.
        • Bussewitz B.W.
        • Hankins T.
        • Ziegler H.L.
        • Philbin T.M.
        Quantitative assessment of the yield of osteoblastic connective tissue progenitors in bone marrow aspirate from the iliac crest, tibia, and calcaneus.
        J Bone Joint Surg Am. 2013; 95: 1312-1316
        • Vangsness Jr., C.T.
        • Sternberg H.
        • Harris L.
        Umbilical cord tissue offers the greatest number of harvestable mesenchymal stem cells for research and clinical application: A literature review of different harvest sites.
        Arthroscopy. 2015; 31: 1836-1843
        • Morikawa D.
        • Johnson J.D.
        • Kia C.
        • et al.
        Examining the potency of subacromial bursal cells as a potential augmentation for rotator cuff healing: An in vitro study.
        Arthroscopy. 2019; 35: 2978-2988
        • Anz A.W.
        • Branch E.A.
        • Rodriguez J.
        • et al.
        Viable stem cells are in the injury effusion fluid and arthroscopic byproducts from knee cruciate ligament surgery: An in vivo analysis.
        Arthroscopy. 2017; 33: 790-797
        • Saw K.Y.
        • Anz A.
        • Merican S.
        • et al.
        Articular cartilage regeneration with autologous peripheral blood progenitor cells and hyaluronic acid after arthroscopic subchondral drilling: a report of 5 cases with histology.
        Arthroscopy. 2011; 27: 493-506
        • Fu W.-L.
        • Zhou C.-Y.
        • Yu J.-K.
        A new source of mesenchymal stem cells for articular cartilage repair: MSCs derived from mobilized peripheral blood share similar biological characteristics in vitro and chondrogenesis in vivo as MSCs from bone marrow in rabbit model.
        Am J Sports Med. 2014; 42: 592-601
        • Chong P.P.
        • Selvaratnam L.
        • Abbas A.A.
        • Kamarul T.
        Human peripheral blood derived mesenchymal stem cells demonstrate similar characteristics and chondrogenic differentiation potential to bone marrow derived mesenchymal stem cells.
        J Orthop Res. 2012; 30: 634-642
        • Hopper N.
        • Wardale J.
        • Brooks R.
        • Power J.
        • Rushton N.
        • Henson F.
        Peripheral blood mononuclear cells enhance cartilage repair in in vivo osteochondral defect model.
        PLoS One. 2015; 10e0133937
        • Mohammadi M.
        • Vaezi M.
        • Chahardouli B.
        • Hadjibabale M.
        • Ghavamzadeh A.
        Effects of short-term pretreatment with atorvastatin on mobilization of hematopoietic progenitor cells: A double-blind, randomized, controlled trial.
        Int J Hematol Oncol Stem Cell Res. 2015; 9: 173-179
        • Reddy R.
        Mobilization and collection of peripheral blood progenitor cells for transplantation.
        Transfus Apher Sci. 2005; 32: 63-72
        • Duhrsen U.
        • Villeval J.-L.
        • Boyd J.
        • Kannourakis G.
        • Morstyn G.
        • Metcalf D.
        Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients.
        Blood. 1988; 72: 2074-2081
        • Korbling M.
        • Przepiorka D.
        • Huh Y.O.
        • et al.
        Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts.
        Blood. 1995; 85: 1659-1665
        • Grigg A.P.
        • Roberts A.W.
        • Raunow H.
        • et al.
        Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers.
        Blood. 1995; 86: 4437-4445
        • Anderlini P.
        • Przepiorka D.
        • Champlin R.
        • Korbling M.
        Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals.
        Blood. 1996; 88: 2819-2825
        • de la Rubia J.
        • de Arriba F.
        • Arbona C.
        • et al.
        Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry.
        Haematologica. 2008; 93: 735-740
        • Holig K.
        • Kramer M.
        • Kroschinsky F.
        • et al.
        Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors.
        Blood. 2009; 114: 3757-3763
        • Martinez C.
        • Urbano-Ispizua A.
        • Rozman C.
        • et al.
        Effects of G-CSF administration and peripheral blood progenitor cell collection in 20 healthy donors.
        Ann Hematol. 1996; 72: 269-272
        • Behfar M.
        • Faghihi-Kashani S.
        • Hosseini A.S.
        • Ghavamzadeh A.
        • Hamidieh A.A.
        Long-term safety of short-term administration of filgrastim (rhG-CSF) and leukophresis procedure in healthy children: application of peripheral blood stem cell collection in pediatric donors.
        Biol Blood Marrow Transplant. 2018; 24: 866-870
        • Dale D.C.
        • Crawford J.
        • Klippel Z.
        • et al.
        A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.
        Support Care Cancer. 2018; 26: 7-20
        • Confer D.L.
        • Miller J.P.
        Long-term safety of filgrastim (rhG-CSF) administration.
        Br J Haematol. 2007; 137 (author reply 79-80): 77-78
        • Cesselli D.
        • Beltrami A.P.
        • Rigo S.
        • et al.
        Multipotent progenitor cells are present in human peripheral blood.
        Circ Res. 2009; 104: 1225-1234
        • Fu S.C.
        • Cheuk Y.C.
        • Yung S.H.
        • Rolf C.G.
        • Chan K.M.
        Systematic review of biological modulation of healing in anterior cruciate ligament reconstruction.
        Orthop J Sports Med. 2014; 2 (2325967114526687)
        • Seta N.
        • Kuwana M.
        Dervation of multipotent progenitors from human circulating CD14+ monocytes.
        Exp Hematol. 2010; 38: 557-563
        • Roufosse C.A.
        • Direkze N.C.
        • Otto W.R.
        • Wright N.A.
        Circulating mesenchymal stem cells.
        Int J Biochem Cell Biol. 2004; 36: 585-597
        • Bucala R.
        • Spiegel L.A.
        • Chesney J.
        • Hogan M.
        • Cerami A.
        Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair.
        Mol Med. 1994; 1: 71-81
        • Kuwana M.
        • Okazaki Y.
        • Kodama H.
        • et al.
        Human circulating CD14+ monocytes as a source of progenitors that exhibit mesenchymal cell differentiation.
        J Leukoc Biol. 2003; 74: 833-845
      1. Anz AW, Hubbard R, Rendos NK, Everts PA, Andrews JR, Hackel JG. Bone marrow aspirate concentrate is equivalent to platelet-rich plasma for the treatment of knee osteoarthritis at 1 year: A prospective, randomized trial [published online February 18, 2020]. Orthop J Sports Med. doi:10.1177/2325967119900958.

        • Kang E.M.
        • Areman E.M.
        • David-Ocampo V.
        • et al.
        Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait.
        Blood. 2002; 99: 850-855
        • Cassano J.M.
        • Kennedy J.G.
        • Ross K.A.
        • Fraser E.J.
        • Goodale M.B.
        • Fortier L.A.
        Bone marrow concentrate and platelet-rich plasma differ in cell distribution and interleukin 1 receptor antagonist protein concentration.
        Knee Surg Sports Traumatol Arthrosc. 2018; 26: 333-342
        • Xiong G.
        • Lingampalli N.
        • Koltsov J.C.B.
        • et al.
        Men and women differ in the biochemical composition of platelet-rich plasma.
        Am J Sports Med. 2018; 46: 409-419
        • Oudelaar B.W.
        • Peerbooms J.C.
        • Huis in 't Veld R.
        • Vochteloo A.J.H.
        Concentration of blood components in commercial platelet-rich plasma separation systems: A review of the literature.
        Am J Sports Med. 2019; 47: 479-487
        • Chahla J.
        • Cinque M.E.
        • Piuzzi N.S.
        • et al.
        A call for standardization in platelet-rich plasma preparation protocols and composition reporting: A systematic review of the clinical orthopaedic literature.
        J Bone Joint Surg Am. 2017; 99: 1769-1779
        • Kang J.
        • Hur J.
        • Kang J.-A.
        • et al.
        Activated platelet supernatant can augment the angiogenic potential of human peripheral blood stem cells mobilized from bone marrow by G-CSF.
        J Mol Cell Cardiol. 2014; 75: 64-75
        • Prabhaker M.
        • Ershler W.B.
        • Longo D.L.
        Bone marrow, thymus and blood: Changes across the lifespan.
        Aging Health. 2009; 5: 385-393
        • Ricci C.
        • Cova M.
        • Kang Y.S.
        • et al.
        Normal age-related patterns of cellular and fatty bone marrow distribution in the axial skeleton: MR imaging study.
        Radiology. 1990; 177: 83-88
        • Evanson J.R.
        • Guyton M.K.
        • Oliver D.L.
        • et al.
        Gender and age differences in growth factor concentrations from platelet-rich plasma in adults.
        Mil Med. 2014; 179: 799-805